NCT02196714View on ClinicalTrials.gov

PK Study of PT003 and PT001 in Japanese Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

September 30, 2014

Conditions
COPD
Interventions
DRUG

Glycopyrronium and Formoterol Fumarate (GFF) Dose 1

Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)

DRUG

Glycopyrronium and Formoterol Fumarate (GFF) Dose 2

Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)

DRUG

Glycopyrronium (GP) Dose 1

Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)

DRUG

Glycopyrronium (GP) Dose 2

Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)

Trial Locations (1)

21201

SNBL, Baltimore

Sponsors
All Listed Sponsors
lead

Pearl Therapeutics, Inc.

INDUSTRY